BMS 986158 is a BET bromodomain inhibitor with anticancer activity.1 It decreases c-Myc expression and induces cancer cell death in c-Myc-driven cancer cell lines in vitro. BMS 986158 inhibits tumor growth in triple-negative breast, colorectal, and lung cancer patient-derived mouse xenograft models.
1.Gavai, A.V., Norris, D., Tortolani, D., et al.Abstract 5789: Discovery of clinical candidate BMS-986158, an oral BET inhibitor, for the treatment of cancerCancer Res.78(13 Supplement)5789-5789(2018)